Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GNSC-001 Gene Therapy for Knee Osteoarthritis
NCT05835895Phase 1Active, not recruiting
- Sponsor
- Genascence Corporation
- Start
- Jun 2023
- Primary completion
- Apr 2025
- Modality
- Gene Editing, Gene Silencing, Viral Vectors
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GNSC-001 in knee osteoarthritis (OA) (6 arms), sponsored by Genascence Corporation. Primary endpoints: Incidence of treatment emergent adverse events at Month 12 and Severity of TEAEs and SAEs at Month 12. Started Jun 2023; status: active, not recruiting.
02
Drugs
GNSC-001
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on NCT05835895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05835895.